Cover Image

Editorial: Natural products modulate the sensitivity of cancer to anti-PD-1 based immunotherapy

Saved in:

Bibliographic Details
Main Authors:	Jean Christopher Chamcheu (Author), Qian Ba (Author), Hang Ma (Author)
Format:	Book
Published:	Frontiers Media S.A., 2023-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Editorial: Chemosensitizing effect of natural products against cancers: Applications in enhancing chemotherapy and immunotherapy
by: Nand K. Roy, et al.
Published: (2022)

Emerging role of natural products in cancer immunotherapy
by: Songtao Dong, et al.
Published: (2022)

The function and regulation of PD-L1 in immunotherapy
by: Libin Guo, et al.
Published: (2017)

An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy
by: Sarah C. Cowles, et al.
Published: (2022)

Editorial: Anti-cancer effects of natural products against reproductive cancers
by: Rosy Iara Maciel Azambuja Ribeiro, et al.
Published: (2023)

Editorial: Natural Product Epigenetic Modulators and Inhibitors
by: Fidele Ntie-Kang, et al.
Published: (2021)

Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C
by: Ping Zhu, et al.
Published: (2023)

Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer
by: Chengpei Zhu, et al.
Published: (2024)

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
by: Yongshuai Jiang, et al.
Published: (2019)

Potential of natural products and gut microbiome in tumor immunotherapy
by: Luchang Cao, et al.
Published: (2024)

Modification of the Tumor Microenvironment Enhances Anti-PD-1 Immunotherapy in Metastatic Melanoma
by: Guilan Shi, et al.
Published: (2022)

Tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for hepatocellular carcinoma: recent research progress
by: Ziwei Li, et al.
Published: (2024)

Strategies to sensitize cancer cells to immunotherapy
by: Andrew George, et al.
Published: (2021)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021)

Editorial: Ovarian cancer-targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more
by: Zhi-Bin Wang, et al.
Published: (2023)

Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis
by: Ze Xiang, et al.
Published: (2022)

Synergistic effect of the anti-PD-1 antibody with blood stable and reduction sensitive curcumin micelles on colon cancer
by: Feirong Gong, et al.
Published: (2021)

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
by: Jin-Yu Sun, et al.
Published: (2020)

Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
by: Xi Chen, et al.
Published: (2020)

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
by: Mengjie Wang, et al.
Published: (2022)

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
by: Hashem O. Alsaab, et al.
Published: (2017)

Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives
by: Yating Zhao, et al.
Published: (2021)

[Translated article] Psoriasis and Anti-PD-1 and Anti-PD-L1 Immunotherapy: Three Cases, a Review of the Literature, and a Proposed Management Algorithm
by: E. Sánchez-Martínez, et al.
Published: (2022)

Cancer Cell Secreted Legumain Promotes Gastric Cancer Resistance to Anti-PD-1 Immunotherapy by Enhancing Macrophage M2 Polarization
by: Xu Pei, et al.
Published: (2024)

Proteomic profiling and biomarker discovery for predicting the response to PD-1 inhibitor immunotherapy in gastric cancer patients
by: Jiangang Sun, et al.
Published: (2024)

Beyond PD-1 Immunotherapy in Malignant Melanoma
by: Dominika Kwiatkowska, et al.
Published: (2019)

Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients
by: Atsuko Ashida, et al.
Published: (2017)

Co‐delivery of dendritic cell vaccine and anti‐PD‐1 antibody with cryomicroneedles for combinational immunotherapy
by: Hao Chang, et al.
Published: (2023)

Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer
by: Ge Y, et al.
Published: (2022)

The Landscape of Nanovectors for Modulation in Cancer Immunotherapy
by: Simona-Ruxandra Volovat, et al.
Published: (2022)

Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study
by: Yiting Sun, et al.
Published: (2021)

Editorial: Targeted Immunotherapy for Cancer
by: Williams V. Williams
Published: (2022)

Adaptive NK Cell Therapy Modulated by Anti-PD-1 Antibody in Gastric Cancer Model
by: Shahrokh Abdolahi, et al.
Published: (2021)

Anti-allergic activity of natural plant products for the treatment of sensitive skin: A review
by: Miao-miao Guo, et al.
Published: (2022)

Lysosomal degradation of PD-L1 is associated with immune-related adverse events during anti-PD-L1 immunotherapy in NSCLC patients
by: Takeru Kashiwada, et al.
Published: (2024)

Exploring prognostic factors for survival in patients with advanced pancreatic cancer undergoing PD-1 inhibitor immunotherapy
by: Yue Ma, et al.
Published: (2024)

Generation of a potent anti-PD-L1-CD47 bispecific antibody with a strong therapeutic and safety profile for cancer immunotherapy
by: Irene Tang, et al.
Published: (2023)

Mesenchymal stem cells elicits Anti-PD1 immunotherapy by targeted delivery of CX3CL1
by: Jize Liu, et al.
Published: (2023)

Biomarker recommendation for PD‐1/PD‐L1 immunotherapy development in pediatric cancer based on digital image analysis of PD‐L1 and immune cells
by: Manuel A Silva, et al.
Published: (2020)

Epithelioid granulomatous lesions express abundant programmed death ligand-1 (PD-L1): a discussion of adverse events in anti-PD-1 antibody-based cancer immunotherapy
by: Terufumi Kubo, et al.
Published: (2021)